Kayla Henson
Primary Care · Benton, KYNPI 1164600466
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 159 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 20.2% — the pattern of someone who eats at a lot of different presentations.
Across 159 payments — averaging $16.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$532
- Novo Nordisk$345
- AbbVie$283
- Astellas Pharma US Inc$157
- Eisai Inc.$155
- Boehringer Ingelheim$119
- plus $1K from 30 others
What the payments were for
- Food & beverage$2,639100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 32 | $532 |
| Novo Nordisk | 21 | $345 |
| AbbVie | 20 | $283 |
| Astellas Pharma US Inc | 6 | $157 |
| Eisai Inc. | 6 | $155 |
| Boehringer Ingelheim | 8 | $119 |
| Johnson & Johnson(2 entities) | 8 | $117 |
| Bayer | 6 | $108 |
| Phathom Pharmaceuticals, Inc. | 7 | $104 |
| Lilly USA, LLC | 5 | $76 |
| Amgen | 3 | $49 |
| Pfizer | 3 | $47 |
| Merck | 3 | $46 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $40 |
| Philips North America LLC | 2 | $39 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $39 |
| AstraZeneca(2 entities) | 2 | $33 |
| Vanda Pharmaceuticals Inc. | 1 | $31 |
| Sanofi | 2 | $30 |
| Amarin Pharma, Inc. | 2 | $27 |
| Axsome Therapeutics, Inc. | 1 | $26 |
| Lundbeck LLC | 1 | $22 |
| Sumitomo Pharma America, Inc. | 1 | $21 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| Kowa Pharmaceuticals America, Inc. | 1 | $19 |
| Dexcom, Inc. | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| Inspire Medical Systems, Inc. | 1 | $16 |
| Collegium Pharmaceutical, Inc. | 1 | $16 |
| Exact Sciences | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
| Corium, LLC | 1 | $13 |
| Genentech USA, Inc. | 1 | $13 |
| GSK | 1 | $11 |
| Biohaven Pharmaceuticals, Inc. | 1 | $11 |
How this compares
$2,639 in reported general payments places this provider in the 85th percentile of 80 primary care providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Synjardy XrEmpagliflozin/Metformin Hcl | 12 | $6,897 |
| Metoprolol Succinate | 15 | $571 |
| Cefdinir | 33 | $415 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 26 | $320 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 36 | $267 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 15 | $225 |
| Doxycycline Monohydrate | 16 | $191 |
| Losartan Potassium | 23 | $181 |
| Methylprednisolone | 30 | $169 |
| Atorvastatin Calcium | 13 | $161 |
| Amlodipine Besylate | 18 | $63 |
| Ciprofloxacin Hcl | 11 | $60 |
| Lisinopril | 17 | $20 |
| Metformin Hcl | 15 | $17 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimSynjardy Xr | $119 | $6,89712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 80 primary care providers in Kentucky.
Other primary care in Benton
- Jessica GoettlLouisville$59K
- Angela ClarkBowling Green$10K
- Tara CoyleShelbyville$7K
- Heather AdamsLexington$7K
- Bridget McKinleyElizabethtown$6K
- Tracy DarlingtonCrestview Hills$6K
- Reagen LoughranLondon$6K
- Jeryl PittmanRichmond$6K
- Samantha FraleyPrestonsburg$3K
- Pamela PhelpsMorgantown$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.